Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Kedudukan dalam Saham #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Harga Saham
$208.57
Modal Pasaran
$368.78B
Perubahan (1 hari)
0.68%
Perubahan (1 tahun)
3.61%
Negara
US
Perdagangan AbbVie Inc. (ABBV)

Kategori

Pendapatan untuk AbbVie Inc. (ABBV)
Pendapatan pada Dec 2025 TTM: $6.60B
Menurut laporan kewangan terkini AbbVie Inc., pendapatan semasa syarikat ialah $6.60B. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $3.72B, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $6.25B. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi AbbVie Inc. dari 2009 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $6.60B 0.00%
2025 $6.60B 77.53%
2024 $3.72B -40.54%
2023 $6.25B -53.62%
2022 $13.48B 3.76%
2021 $12.99B 282.25%
2020 $3.40B -59.67%
2019 $8.43B 62.13%
2018 $5.20B -32.74%
2017 $7.73B -1.99%
2016 $7.88B 18.65%
2015 $6.65B 180.50%
2014 $2.37B -55.57%
2013 $5.33B -6.86%
2012 $5.73B 56.08%
2011 $3.67B -24.15%
2010 $4.84B -18.73%
2009 $5.95B 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$25.73B 290.02%
US
$12.40B 87.99%
GB
$32.58B 393.88%
US
$16.35B 147.87%
CH
$21.07B 219.34%
US